WO2014195810A3 - Compositions and methods for the treatment of diabetes and pre-diabetes - Google Patents
Compositions and methods for the treatment of diabetes and pre-diabetes Download PDFInfo
- Publication number
- WO2014195810A3 WO2014195810A3 PCT/IB2014/058634 IB2014058634W WO2014195810A3 WO 2014195810 A3 WO2014195810 A3 WO 2014195810A3 IB 2014058634 W IB2014058634 W IB 2014058634W WO 2014195810 A3 WO2014195810 A3 WO 2014195810A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diabetes
- compositions
- treatment
- methods
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201509782TA SG11201509782TA (en) | 2013-06-04 | 2014-02-12 | Compositions and methods for the treatment of diabetes and pre-diabetes |
PCT/IN2014/000089 WO2014195961A1 (en) | 2013-06-04 | 2014-02-12 | Compositions and methods for the treatment of diabetes and pre-diabetes |
AU2014276346A AU2014276346A1 (en) | 2013-06-04 | 2014-02-12 | Compositions and methods for the treatment of diabetes and pre-diabetes |
CA2914461A CA2914461A1 (en) | 2013-06-04 | 2014-02-12 | Compositions and methods for the treatment of diabetes and pre-diabetes |
EP14725542.6A EP3004049B1 (en) | 2013-06-04 | 2014-02-12 | Compositions and methods for the treatment of diabetes and pre-diabetes |
US14/244,911 US8952068B2 (en) | 2013-06-04 | 2014-04-04 | Compositions for the treatment of diabetes and pre-diabetes |
US14/583,117 US9174931B2 (en) | 2013-06-04 | 2014-12-25 | Compositions for the treatment of diabetes and pre-diabetes |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2448/CHE/2013 | 2013-06-04 | ||
IN2448CH2013 | 2013-06-04 | ||
IBPCT/IB2013/059680 | 2013-10-26 | ||
PCT/IB2013/059680 WO2014080307A2 (en) | 2012-11-21 | 2013-10-26 | Compositions and methods for the treatment of diabetes and pre-diabetes |
IN5592CH2013 | 2013-12-04 | ||
IN5592/CHE/2013 | 2013-12-04 | ||
IN315CH2014 | 2014-01-25 | ||
IN315/CHE/2014 | 2014-01-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014195810A2 WO2014195810A2 (en) | 2014-12-11 |
WO2014195810A3 true WO2014195810A3 (en) | 2017-03-09 |
Family
ID=52008658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/058634 WO2014195810A2 (en) | 2013-06-04 | 2014-01-29 | Compositions and methods for the treatment of diabetes and pre-diabetes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014195810A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015022613A1 (en) * | 2013-08-11 | 2015-02-19 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
WO2016117465A1 (en) * | 2015-01-19 | 2016-07-28 | 昭和電工株式会社 | Compound, salt of compound, external agent for skin, cosmetic, and food additive |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011106688A1 (en) * | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
US20120178813A1 (en) * | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
-
2014
- 2014-01-29 WO PCT/IB2014/058634 patent/WO2014195810A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011106688A1 (en) * | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
US20120178813A1 (en) * | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
Also Published As
Publication number | Publication date |
---|---|
WO2014195810A2 (en) | 2014-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014087307A3 (en) | Compositions and methods for the treatment of metabolic syndrome and diabetes | |
WO2013175377A3 (en) | Compositions and methods for treatment of mucositis | |
WO2016046680A3 (en) | Compositions and methods for the treatment of liver metabolic diseases | |
PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
WO2013175376A3 (en) | Compositions and methods for the treatment of local pain | |
MX2019007713A (en) | Compositions and methods for the treatment of chronic pain. | |
WO2014174425A3 (en) | Compositions and methods for the treatment of orthostasis and neurological diseases | |
WO2011085643A8 (en) | Fused pyridine derivatives | |
WO2014068463A3 (en) | Compositions and methods for the treatment of inflammation and metabolic disorders | |
WO2014091384A3 (en) | Compositions and methods for the treatment of mucositis | |
WO2014080307A3 (en) | Compositions and methods for the treatment of diabetes and pre-diabetes | |
WO2013175359A3 (en) | Compositions and methods for the treatment of multiple sclerosis | |
WO2014106804A3 (en) | Compositions and methods for the treatment of metabolic syndrome and diabetes | |
WO2014195810A3 (en) | Compositions and methods for the treatment of diabetes and pre-diabetes | |
WO2013167998A3 (en) | Compositions and methods for the treatment of autonomic and other neurological disorders | |
WO2014087323A3 (en) | Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases | |
WO2015015403A3 (en) | Compositions and methods for the treatment of diabetes and pre-diabetes | |
WO2014195850A3 (en) | Compositions and methods for the treatment of neurologic diseases and neurological disorders | |
MX2019005568A (en) | Compositions and methods for the treatment of gastrointestinal polyps. | |
WO2013175344A3 (en) | Compositions and methods for treatment of peridontitis and rheumatoid arthritis | |
WO2014097137A3 (en) | Compositions and methods for the treatment of seizures and neurologic diseases | |
WO2013167995A3 (en) | Compositions and methods for the treatment of hyperglycemia | |
WO2014106805A3 (en) | Fatty acid conjugates and their uses | |
WO2015028976A3 (en) | Compounds and methods for the treatment of inflammatory diseases | |
WO2014083476A3 (en) | Compositions and methods for the treatment of metabolic and lipid disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14808289 Country of ref document: EP Kind code of ref document: A2 |